• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Topics » Addiction Treatment

Addiction Treatment
Addiction Treatment RSS Feed RSS

Fact Sheet

Topiramate (Eprontia, Qudexy XR, Topamax, Trokendi XR) Fact Sheet

April 21, 2026
Michael Weaver, MD, FASAM, Daniel Carlat, MD, and Talia Puzantian, PharmD, BCPP

Dr. Carlat, Dr. Weaver, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Naltrexone, an opioid antagonist, is the first-line medication for alcohol use disorder (AUD)—though it is also approved for opioid use disorder (OUD).




Read More
Fact Sheet

Naltrexone (ReVia, Vivitrol) Fact Sheet

April 21, 2026
Michael Weaver, MD, FASAM, Daniel Carlat, MD, and Talia Puzantian, PharmD, BCPP

Dr. Carlat, Dr. Weaver, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Naltrexone, an opioid antagonist, is the first-line medication for alcohol use disorder (AUD)—though it is also approved for opioid use disorder (OUD).




Read More
Fact Sheet

Gabapentin (Gralise, Horizant, Neurontin) Fact Sheet

April 21, 2026
Michael Weaver, MD, FASAM, Daniel Carlat, MD, and Talia Puzantian, PharmD, BCPP

Dr. Carlat, Dr. Weaver, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Gabapentin is effective as an off-label medication to ease alcohol withdrawal symptoms and to reduce cravings over the long term in patients with alcohol use disorder (AUD).




Read More
Fact Sheet

Disulfiram (Antabuse) Fact Sheet

April 21, 2026
Michael Weaver, MD, FASAM, Daniel Carlat, MD, and Talia Puzantian, PharmD, BCPP

Dr. Carlat, Dr. Weaver, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Disulfiram is an aversive treatment, causing a buildup of ethanol’s metabolite acetaldehyde in the serum, which in turn causes symptoms such as flushing, dizziness, nausea, and vomiting if patient consumes alcohol.



Read More
Fact Sheet

Acamprosate (Campral) Fact Sheet [G]

April 21, 2026
Michael Weaver, MD, FASAM, Daniel Carlat, MD, and Talia Puzantian, PharmD, BCPP

Dr. Carlat, Dr. Weaver, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Acamprosate is best for maintaining abstinence in patients who have already quit drinking, but it can be helpful even after patients relapse. Naltrexone is the better choice for patients who are still drinking, since it is better at helping patients quit. Acamprosate is preferred over naltrexone in patients with hepatic impairment.


Read More

Learning Objectives, Drug Trends CATR, April/May/June 2026

April 1, 2026
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

After reading these articles, you should be able to…


Read More

CME Post-Test, Drug Trends, CATR, April/May/June 2026

April 1, 2026
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

By successfully completing the test you will be awarded a certificate for 2 CME credits.


Read More
Expert Q&A

Prescription Drug Misuse and Diversion in Correctional Settings

April 1, 2026
Brian Holoyda, MD, MPH, MBA
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Brian Holoyda, MD, MPH, MBA

Chief Psychiatrist, Contra Costa County Detention Health Services, Martinez, CA.

Dr. Holoyda has no financial relationships with companies related to this material.

Medication misuse in correctional settings reveals how prescribing practices intersect with diversion risk. Dr. Holoyda discusses high demand agents such as gabapentin and bupropion, system level strategies like crush and float, and how to balance safety with adequate treatment. The lessons extend beyond jails to hospitals and outpatient units.


Read More
CATR_AprMayJun2026.jpg
Clinical Update

What Psychiatrists Should Know About Inhalants

April 1, 2026
Jared Bozeman, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Jared Bozeman, MD. Psychiatrist, Montana VA Healthcare System, Bozeman, MT.

Dr. Bozeman has no financial relationships with companies related to this material.

Inhalant misuse is often missed in routine practice, especially when drug screens are negative. This update reviews common products, acute risks such as sudden sniffing death, long-term neurologic injury, and nitrous oxide related B12 deficiency. Learn practical screening questions, red flags, and management strategies relevant to both adolescents and adults.


Read More
CATR_QA1 Joseph Palamar_photo_sm.png
Expert Q&A

Trends in Illicit Drug Use

April 1, 2026
Joseph Palamar, PhD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Joseph Palamar, PhD

Professor of Population Health, NYU Langone Health, New York, NY; Deputy Director, National Drug Early Warning System.

Dr. Palamar has no financial relationships with companies related to this material.

Illicit fentanyl now dominates the opioid supply and is often mixed with other dangerous drugs. Dr. Palamar reviews many of these drugs including xylazine, medetomidine, nitazenes, and even industrial chemicals. He explains how these additives alter risk, why geography matters, and how clinicians can stay current using regional alerts and drug checking data.


Read More
Previous 1 2 3 4 5 6 7 8 9 … 63 64 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • PB5e_3DCover.png

    Psychiatry Practice Boosters, Fifth Edition (2026)

    This fifth edition teaches you the key points of 66 of the most clinically relevant studies in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2772531237.jpg
    General Psychiatry

    Gender Affirming Care in Exile: The Lawsuits

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.